David Lebovitz

Stock Analyst at Citigroup

(1.94)
# 1030
Out of 5,328 analysts
126
Total ratings
73.68%
Success rate
8.58%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
338 351
255.12 37.58% 31 Mar 21, 2025
MDGL Madrigal Pharmaceuti...
Maintains: Strong Buy
378 469
326.72 43.55% 4 Feb 27, 2025
BMRN Biomarin Pharmaceuti...
Maintains: Neutral
81 82
62.7 30.78% 3 Feb 20, 2025
CRNX Crinetics Pharmaceut...
Maintains: Strong Buy
70 74
33.6 120.24% 2 Nov 14, 2024
MIRM Mirum Pharmaceutical...
Maintains: Strong Buy
37 38
43.47 -12.58% 1 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Sell
29 17
49.5 -65.66% 5 Oct 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
111 92
99.27 -7.32% 6 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
57 54
63.8 -15.36% 5 Aug 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
408 372
n/a n/a 5 May 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
11 10
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
38 35
31.79 10.1% 6 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
16 17
1.7 900% 11 Apr 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
12 11
0.93 1082.8% 7 Feb 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
193 220
n/a n/a 5 Feb 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
50 500
n/a n/a 2 Dec 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 44
n/a n/a 10 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
194 199
166.64 19.42% 11 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
510 480
6.78 6979.65% 2 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
27 26
n/a n/a 2 Aug 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
119 129
n/a n/a 3 Mar 6, 2018